Premenstrual disorders

American Journal of Obstetrics and Gynecology

Volumn 218, Issue 1, 2018, Pages 68-74

  Yonkers, Kimberly Ann ^a   Simoni, Michael K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

menstrual cycle; premenstrual disorder; premenstrual dysphoric disorder; premenstrual symptoms; premenstrual syndrome; premenstrual tension

Indexed keywords

CONTRACEPTIVE AGENT; HORMONE ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; ANDROSTANE DERIVATIVE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; GONADORELIN;

ALTERNATIVE MEDICINE; EVIDENCE BASED PRACTICE; FEMALE; HUMAN; MENSTRUAL CYCLE; MENSTRUATION DISORDER; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; AGONISTS; COGNITIVE THERAPY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EXERCISE; HYSTERECTOMY; OVARIECTOMY; PSYCHOLOGY; SALPINGECTOMY;

ANDROSTENES; COGNITIVE THERAPY; COMPLEMENTARY THERAPIES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ETHINYL ESTRADIOL; EXERCISE; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; HYSTERECTOMY; OVARIECTOMY; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; RISK FACTORS; SALPINGECTOMY; SEROTONIN UPTAKE INHIBITORS;

EID: 85023632423     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2017.05.045     Document Type: Review

References (74)

1. Frank, R.T., The hormonal causes of premenstrual tension. Arch Neurol Psychiatry 26 (1931), 1053–1057.
2. Greene, R., Dalton, K., The premenstrual syndrome. Br Med J 1 (1953), 1007–1014.
3. O'Brien, P.M.S., Backstrom, T., Brown, C., et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Arch Womens Ment Health 14 (2011), 13–21.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington (DC): American Psychiatric Association, 2013.
5. Rubinow, D.R., Roy-Byrne, P., Premenstrual syndromes: overview from a methodologic perspective. Am J Psychiatry 141 (1984), 163–172.
6. Green, L., O'Brien, P., Panay, N., Craig, M., Royal College of Obstetricians and Gynecologists. Management of premenstrual symptoms. BJOG 124 (2016), e73–e105.
7. Hartlage, S.A., Freels, S., Gotman, N., Yonkers, K., Criteria for premenstrual dysphoric disorder: secondary analyses of relevant data sets. Arch Gen Psychiatry 69 (2012), 300–305.
8. Borenstein, J.E., Dean, B.B., Leifke, E., Korner, P., Yonkers, K.A., Differences in symptom scores and health outcomes in premenstrual syndrome. J Womens Health (Larchmt) 16 (2007), 1139–1144.
9. Qiao, M., Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in a population-based sample in China. Eur J Obstet Gynecol Reprod Biol 162 (2012), 83–86.
10. Cohen, L., Soares, C., Otto, M., Sweeney, B., Liberman, R., Harlow, B., Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles. J Affect Disord 70 (2002), 125–132.
11. Gehlert, S., Song, I.H., Chang, C.H., Hartlage, S.A., The prevalence of premenstrual dysphoric disorder in a randomly selected group of urban and rural women. Psychol Med 39 (2009), 129–136.
12. Dennerstein, L., Lehert, P., Heinemann, K., Epidemiology of premenstrual symptoms and disorders. Menopause Int 18 (2012), 48–51.
13. Masho, S.W., Adera, T., South-Paul, J., Obesity as a risk factor for premenstrual syndrome. J Psychosom Obstet Gynaecol 26 (2005), 33–39.
14. Pilver, C.E., Kasl, S., Desai, R., Levy, B.R., Health advantage for black women: patterns in pre-menstrual dysphoric disorder. Psychol Med 41 (2011), 1741–1750.
15. Wittchen, H., Becker, E., Lieb, R., Krause, P., Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 32 (2002), 119–132.
16. Chocano-Bedoya, P.O., Intake of selected minerals and risk of premenstrual syndrome. Am J Epidemiol 177 (2013), 1118–1127.
17. Bertone-Johnson, E.R., Hankinson, S.E., Willett, W.C., Johnson, S.R., Manson, J.E., Adiposity and the development of premenstrual syndrome. J Womens Health (Larchmt) 19 (2010), 1955–1962.
18. Hashemi, S., Ramezani Tehrani, F., Mohammadi, N., et al. Comparison of metabolic and hormonal profiles of women with and without premenstrual syndrome: a community-based cross-sectional study. Int J Endocrinol Metab, 14, 2016, e28422.
19. Perkonigg, A., Yonkers, K., Pfister, H., Lieb, R., Wittchen, H.-U., Risk factors for premenstrual dysphoric disorder in a community sample of young women: the role of traumatic events and posttraumatic stress disorder. J Clin Psychiatry 65 (2004), 1314–1322.
20. Bertone-Johnson, E.R., Whitcomb, B.W., Missmer, S.A., Manson, J.E., Hankinson, S.E., Rich-Edwards, J.W., Early life emotional, physical, and sexual abuse and the development of premenstrual syndrome: a longitudinal study. J Womens Health (Larchmt) 23 (2014), 729–739.
21. Graze, K.K., Nee, J., Endicott, J., Premenstrual depression predicts future major depressive disorder. Acta Psychiatr Scand 81 (1990), 201–205.
22. Kendler, K.S., Silberg, J.L., Neale, M.C., Kessler, R.C., Heath, A.C., Eaves, L.J., Genetic and environmental factors in the etiology of menstrual, premenstrual and neurotic symptoms: a population-based twin study. Psychol Med 22 (1992), 85–100.
23. Condon, J.T., The premenstrual syndrome: a twin study. Br J Psychiatry 162 (1993), 481–486.
24. Schmidt, P.J., Martinez, P.E., Nieman, L.K., et al. Premenstrual dysphoric disorder symptoms following ovarian suppression: triggered by change in ovarian steroid levels but not continuous stable levels. Am J Psychiatry, 2017 Apr 21 appiajp201716101113. http://dx.doi.org/10.1176/appi.ajp.2017.16101113. [Epub ahead of print].
25. Lovick, T., SSRIs and the female brain–potential for utilizing steroid-stimulating properties to treat menstrual cycle-linked dysphorias. J Psychopharmacol 27 (2013), 1180–1185.
26. Backstrom, T., Haage, D., Lofgren, M., et al. Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons. Neuroscience 191 (2011), 46–54.
27. Martinez, P.E., Rubinow, D.R., Nieman, L.K., et al. 5alpha-Reductase inhibition prevents the luteal phase increase in plasma allopregnanolone levels and mitigates symptoms in women with premenstrual dysphoric disorder. Neuropsychopharmacology 41 (2016), 1093–1102.
28. Bixo, M., Ekberg, K., Poromaa, I.S., et al. Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)–a randomized controlled trial. Psychoneuroendocrinology 80 (2017), 46–55.
29. Gracia, C.R., Freeman, E.W., Sammel, M.D., Lin, H., Sheng, L., Frye, C., Allopregnanolone levels before and after selective serotonin reuptake inhibitor treatment of premenstrual symptoms. J Clin Psychopharmacol 29 (2009), 403–405.
30. Eriksson, E., SSRIs probably counteract premenstrual syndrome by inhibiting the serotonin transporter. J Psychopharmacol 28 (2014), 173–174.
31. Carlsson, M., Carlsson, A., A regional study of sex differences in rat brain serotonin. Prog Neuropsychopharmacol Biol Psychiatry 12 (1988), 53–61.
32. Hiroi, R., McDevitt, R.A., Neumaier, J.F., Estrogen selectively increases tryptophan hydroxylase-2 mRNA expression in distinct subregions of rat midbrain raphe nucleus: association between gene expression and anxiety behavior in the open field. Biol Psychiatry 60 (2006), 288–295.
33. Bethea, C.L., Lu, N.Z., Gundlah, C., Streicher, J.M., Diverse actions of ovarian steroids in the serotonin neural system. Front Neuroendocrinol 23 (2002), 41–100.
34. Menkes, D.B., Coates, D.C., Fawcett, J.P., Acute tryptophan depletion aggravates premenstrual syndrome. J Affect Disord 32 (1994), 37–44.
35. Roca, C., Schmidt, P., Smith, M., Danaceau, M., Murphy, D., Rubinow, D., Effects of metergoline on symptoms in women with premenstrual dysphoric disorder. Am J Psychiatry 159 (2002), 1876–1881.
36. Yonkers, K.A., O'Brien, P.M., Eriksson, E., Premenstrual syndrome. Lancet 371 (2008), 1200–1210.
37. Hantsoo, L., Epperson, C.N., Premenstrual dysphoric disorder: epidemiology and treatment. Curr Psychiatry Rep, 17, 2015, 87.
38. Comasco, E., Sundstrom-Poromaa, I., Neuroimaging the menstrual cycle and premenstrual dysphoric disorder. Curr Psychiatry Rep, 17, 2015, 77.
39. Comasco, E., Hahn, A., Ganger, S., et al. Emotional fronto-cingulate cortex activation and brain derived neurotrophic factor polymorphism in premenstrual dysphoric disorder. Hum Brain Mapp 35 (2014), 4450–4458.
40. Protopopescu, X., Tuescher, O., Pan, H., et al. Toward a functional neuroanatomy of premenstrual dysphoric disorder. J Affect Disord 108 (2008), 87–94.
41. Baller, E., Wei, S.-M., Kohn, P., et al. Abnormalities of dorsolateral prefrontal function in women with premenstrual dysphoric disorder: a multimodal neuroimaging study. Am J Psychiatry 170 (2013), 305–314.
42. Prior, J.C., Vigna, Y., Sciarretta, D., Alojado, N., Schulzer, M., Conditioning exercise decreases premenstrual symptoms: a prospective, controlled 6-month trial. Fertil Steril 47 (1987), 402–408.
43. Sayegh, R., Schiff, I., Wurtman, J., Spiers, P., McDermott, J., Wurtman, R., The effect of a carbohydrate-rich beverage on mood, appetite, and cognitive function in women with premenstrual syndrome. Obstet Gynecol 86 (1995), 520–528.
44. Hunter, M.S., Ussher, J.M., Browne, S.J., Cariss, M., Jelley, R., Katz, M., A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol 23 (2002), 193–199.
45. Halbreich, U., Smoller, J.W., Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 58 (1997), 399–402.
46. Marjoribanks, J., Brown, J., O'Brien, P.M., Wyatt, K., Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev, 6, 2013, Cd001396.
47. Kornstein, S.G., Pearlstein, T.B., Fayyad, R., Farfel, G.M., Gillespie, J.A., Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: efficacy of 3 dosing strategies. J Clin Psychiatry 67 (2006), 1624–1632.
48. Yonkers, K.A., Kornstein, S.G., Gueorguieva, R., Merry, B., Van Steenburgh, K., Altemus, M., Symptom-onset dosing of sertraline for the treatment of premenstrual dysphoric disorder: a randomized clinical trial. JAMA Psychiatry 72 (2015), 1037–1044.
49. Pearlstein, T.B., Bachmann, G.A., Zacur, H.A., Yonkers, K.A., Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 72 (2005), 414–421.
50. Yonkers, K.A., Brown, C., Pearlstein, T.B., Foegh, M., Sampson-Landers, C., Rapkin, A., Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 106 (2005), 492–501.
51. Freeman, E.W., Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder. Eur J Contracept Reprod Health Care 7 (2002), 27–34.
52. Halbreich, U., Freeman, E.W., Rapkin, A.J., et al. Continuous oral levonorgestrel/ethinyl estradiol for treating premenstrual dysphoric disorder. Contraception 85 (2012), 19–27.
53. Freeman, E.W., An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome. Contraception 85 (2012), 437–445.
54. Naheed, B., Kuiper, J.H., Uthman, O.A., O'Mahony, F., O'Brien, P.M., Non-contraceptive estrogen-containing preparations for controlling symptoms of premenstrual syndrome. Cochrane Database Syst Rev, 3, 2017, Cd010503.
55. Ford, O., Lethaby, A., Roberts, H., Mol, B.W., Progesterone for premenstrual syndrome. Cochrane Database Syst Rev, 3, 2012, Cd003415.
56. Wyatt, K.M., Dimmock, P.W., Ismail, K.M.K., Jones, P.W., O'Brien, P.M.S., The effectiveness of GnRHa with and without ‘add-back’ therapy in treating premenstrual syndrome: a meta analysis. BJOG 111 (2004), 585–593.
57. Brown, C.S., Ling, F.W., Andersen, R.N., Farmer, R.G., Arheart, K.L., Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol 84 (1994), 779–786.
58. Muse, K.N., Cetel, N.S., Futterman, L.A., Yen, S.S.C., The premenstrual syndrome: effects of “medical ovariectomy”. N Engl J Med 311 (1984), 1345–1349.
59. Wyatt, K.M., Dimmock, P.W., Jones, P.W., Shaughn O'Brien PM. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ 318 (1999), 1375–1381.
60. Verkaik, S., Kamperman, A.M., van Westrhenen, R., Schulte, P.F.J., The treatment of premenstrual syndrome with preparations of Vitex agnus-castus: a systematic review and meta-analysis. Am J Obstet Gynecol 217 (2017), 150–166.
61. Ozgoli, G., Selselei, E.A., Mojab, F., Majd, H.A., A randomized, placebo-controlled trial of Ginkgo biloba L. in treatment of premenstrual syndrome. J Altern Complement Med 15 (2009), 845–851.
62. Canning, S., Waterman, M., Orsi, N., Ayres, J., Simpson, N., Dye, L., The efficacy of Hypericum perforatum (St John's wort) for the treatment of premenstrual syndrome: a randomized, double-blind, placebo-controlled trial. CNS Drugs 24 (2010), 207–225.
63. Thys-Jacob, S., Alvir, M.J., Calcium-regulating hormones across the menstrual cycle: evidence of a secondary hyperparathyroidism in women with PMS. J Clin Endocrinol Metab 80 (1995), 2227–2232.
64. Thys-Jacobs, S., Starkey, P., Bernstein, D., Tian, J., Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol 179 (1998), 444–452.
65. Shobeiri, F., Araste, F.E., Ebrahimi, R., Jenabi, E., Nazari, M., Effect of calcium on premenstrual syndrome: a double-blind randomized clinical trial. Obstet Gynecol Sci 60 (2017), 100–105.
66. Yonkers, K.A., Pearlstein, T.B., Gotman, N., A pilot study to compare fluoxetine, calcium, and placebo in the treatment of premenstrual syndrome. J Clin Psychopharmacol 33 (2013), 614–620.
67. Endicott, J., Nee, J., Harrison, W., Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Womens Ment Health 9 (2006), 41–49.
68. Mortola, J.F., Girton, L., Beck, L., Yen, S.S.C., Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: the Calendar of Premenstrual Experiences. Obstet Gynecol Clin North Am 76 (1990), 302–307.
69. Lopez, L.M., Kaptein, A.A., Helmerhorst, F.M., Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev, 2, 2012, CD006586.
70. Yonkers, K.A., Cameron, B., Gueorguieva, R., Altemus, M., Kornstein, S.G., The influence of cyclic hormonal contraception on expression of premenstrual syndrome. J Womens Health (Larchmt) 26 (2017), 321–328.
71. Halbreich, U., Bergeron, R., Yonkers, K.A., Freeman, E., Stout, A.L., Cohen, L., Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 100 (2002), 1219–1229.
72. Segebladh, B., Borgstrom, A., Nyberg, S., Bixo, M., Sundstrom-Poromaa, I., Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. Am J Obstet Gynecol 201 (2009), 139.e1–139.e8.
73. Di Carlo, C., Palomba, S., Tommaselli, G.A., Guida, M., Di Spiezio Sardo, A., Nappi, C., Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome. Fertil Steril 75 (2001), 380–384.
74. Hammarback, S., Backstrom, T., Induced anovulation as treatment of premenstrual tension syndrome. A double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet Gynecol Scand 67 (1988), 159–166.